Catalyst Event

Bristol-Myers Squibb Co (BMY) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/11/2026, 12:00:00 AM

OtherSentiment: Negative

Competitor Takeda announced its experimental drug zasocitinib demonstrated superiority over BMY's Sotyktu in a head-to-head Phase 3 trial for psoriasis, potentially impacting Sotyktu's market share. This significant competitive threat is estimated to have a 10% or greater price impact.

Korean Translation

경쟁사 다케다, 건선 치료제 후보물질 자소시티닙(zasocitinib)이 BMY의 소틱투(Sotyktu)와의 직접 비교 3상 임상시험에서 우월성을 입증했다고 발표함. 이는 소틱투의 시장 점유율에 중대한 위협이 되어 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline